Cambium Oncology and Orient Euro Pharma (OEP) announce a strategic partnership in which OEP has invested $5M in Cambium Oncology. This will accelerate the clinical development of Cambium Oncology’s lead therapeutic candidate, ANT308, a FIRST-IN-CLASS vasoactive intestinal peptide (VIP) receptor antagonist designed to restore anti-cancer T-cell function. This investment is in addition to $2.4M recently received from the NIH.
- PROOF-OF-CONCEPT: ANT308 has shown strong single-agent anti-leukemia activity in two AML mouse models and synergistic effects with anti-PD-1 checkpoint inhibitors in three pancreatic cancer (PDAC) models.
- Broad Therapeutic Potential: This platform technology has applications across hematologic malignancies and solid tumors, with the potential to enhance response rates in checkpoint inhibitor-resistant cancers.
HealthTech Insights: Thrive Global Works with Eli Lilly and Company to Offer Healthy Behaviors Tools and Resources to Improve Health Outcomes
ANT308 is a proprietary small-molecule antagonist that blocks VIP-receptor signaling on human T cells, overcoming immune suppression in the tumor microenvironment. Unlike traditional therapies, ANT308 is mutation-agnostic and has demonstrated no dose-limiting toxicities in preclinical studies.
HealthTech Insights: Goertek Unveils Next-Generation Smart Ring Reference Designs: A Leap Forward in Health Monitoring and Interactive Technology
With over 40 years of pharmaceutical industry experience, OEPI brings regulatory expertise, manufacturing capabilities, and commercial reach to help Cambium Oncology scale development and accelerate clinical translation. This partnership represents a key milestone in advancing novel immuno-oncology therapeutics to market.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
